grant
The Role of Egfl6 in Tumor Immunity
Organization MAGEE-WOMEN'S RES INST AND FOUNDATIONLocation Pittsburgh, UNITED STATESPosted 7 Jun 2023Deadline 31 May 2028
NIHUS FederalResearch GrantFY2025AdenocarcinomaAdjuvantAntibodiesAntibody TherapyB7-H1Blood NeutrophilBlood Polymorphonuclear NeutrophilBlood granulocytic cellBlood monocyteBone MarrowBone Marrow Reticuloendothelial SystemCAGBCD274CD8CD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCD8BCD8B1CD8B1 geneCGCBCSIFCSIF-10CXCL2CXCL2 geneCancer ModelCancer PatientCancerModelCancersCarcinomaCell BodyCell Communication and SignalingCell FunctionCell LocomotionCell MigrationCell MovementCell PhysiologyCell ProcessCell SignalingCellsCellular FunctionCellular Immune FunctionCellular MigrationCellular MotilityCellular PhysiologyCellular ProcessCheckpoint inhibitorChemokine, CXC Motif, Ligand 2Cytokine Synthesis Inhibitory FactorCytotoxic cellDKFZP564P2063DKFZP564P2063 GeneDataDeath RateDevelopmentEGF Repeat-Containing Protein 6 GeneEGF-Like 6EGF-Like 6 GeneEGF-Like DomainEGFL6EGFL6 geneEffectivenessEffector CellEngraftmentEpidermal Growth Factor-Like Protein 6 GeneEpithelial cancerEventGRO Protein, BetaGRO2GRO2 OncogeneGRObGROβGene ExpressionGoalsGranular LeukocytesGranulocytic cellGrowth AgentsGrowth FactorGrowth SubstancesHumanIL-10IL10IL10AImaging ProceduresImaging TechnicsImaging TechniquesImmune RegulatorsImmune checkpoint inhibitorImmune mediated therapyImmune responseImmunityImmunocompetentImmunologically Directed TherapyImmunomodulationImmunomodulatorsImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapyIntegrinsIntegrins Extracellular MatrixInterleukin 10 PrecursorInterleukin-10Intracellular Communication and SignalingJUN Family GeneJUN Proto-oncogene FamilyJUN geneK lymphocyteLIAGLYT3MAC387MAEGMAM Domain- and EGF Domain-Containing GeneMAM- and EGF-Containing GeneMIP-2AMIP2-alphaMIP2AMIP2αMRP14Malignant AdenomaMalignant CellMalignant Epithelial NeoplasmsMalignant Epithelial TumorsMalignant NeoplasmsMalignant Ovarian NeoplasmMalignant Ovarian TumorMalignant TumorMalignant Tumor of the OvaryMalignant neoplasm of ovaryMarrow NeutrophilMarrow monocyteMediatingMiceMice MammalsModern ManMurineMusMyeloid CellsMyeloid-derived suppressor cellsNK CellsNatural Killer CellsNeutrophilic GranulocyteNeutrophilic LeukocyteOvarian TumorOvary CancerOvary NeoplasmsOvary TumorPD-L1PDL-1PhenotypePhosphorylationPolymorphonuclear CellPolymorphonuclear LeukocytesPolymorphonuclear NeutrophilsProductionProgrammed Cell Death 1 Ligand 1Programmed Death Ligand 1ProliferatingProtein PhosphorylationProtein SecretionProteinsProteins Growth FactorsRNA SeqRNA sequencingRNAseqRecombinant ProteinsRefractoryResistanceRoleS100A9S100A9 geneSCYB2SamplingSignal TransductionSignal Transduction SystemsSignalingSmall Inducible Cytokine Subfamily B, Member 2SpleenSpleen Reticuloendothelial SystemSubcellular ProcessT8 CellsT8 LymphocytesTestingTherapeuticTimeTransgenic MiceTumor ImmunityTumor-associated macrophagesW80Workangiogenesisanti-tumor immune responseanti-tumor immunityantibody based therapiesantibody treatmentantibody-based therapeuticsantibody-based treatmentantitumor immunitybiological signal transductionc junc-jun Genecancer cellcancer immunitycancer microenvironmentcancer typecell motilitycheck point immunotherapycheck point inhibitor therapycheck point inhibitory therapycheck point therapycheckpoint immunotherapycheckpoint inhibitor therapycheckpoint inhibitory therapycheckpoint therapycompare to controlcomparison controlcytotoxiccytotoxic CD8 T cellscytotoxic CD8 T lymphocytedetermine efficacydevelopmentalefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationepithelial carcinomaevaluate efficacyexamine efficacyextracellulargranulocytehost responseimmune check point inhibitorimmune check point therapyimmune checkpoint therapyimmune competentimmune functionimmune microenvironmentimmune modulationimmune modulatorsimmune regulationimmune suppressionimmune suppressive activityimmune suppressive functionimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunologic reactivity controlimmunomodulatoryimmunomodulatory moleculesimmunoregulationimmunoregulatorimmunoregulatoryimmunoregulatory moleculesimmunoresponseimmunosuppressive activityimmunosuppressive functionimmunosuppressive microenvironmentimmunosuppressive myeloid cellsimmunosuppressive responseimmunosuppressive tumor microenvironmentimprovedinhibitorknock-downknockdownmacrophage inflammatory protein 2malignancymonocytemortality ratemortality ratiomouse modelmultiplexed imagingmurine modelmyeloid suppressor cellsmyeloid-derived suppressive cellsneoplasm/cancerneutralizing antibodyneutrophilnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovelnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachovarian cancerovarian neoplasmoverexpressoverexpressionpreventpreventingprogrammed cell death ligand 1programmed cell death protein ligand 1programsprotein death-ligand 1protein expressionrecruitresistantresponseresponse to therapyresponse to treatmentsocial rolesuppressive myeloid cellstherapeutic responsetherapeutic targettherapy responsetranscriptome sequencingtranscriptomic sequencingtreatment responsetreatment responsivenesstumortumor immune microenvironmenttumor microenvironmenttumor-immune system interactionstumorigenicβ-GRO protein
Description preview
Ovarian cancer (OvCa) has an extremely high mortality rate, indicating a clear need for new therapeutic
approaches. One such approach is immune checkpoint inhibitor (ICI) therapy. Unfortunately, despite the
presence of anti-tumor effector cells in many OvCa patients, ICI therapies have poor response rates in OvCa.
One reason for this may large…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click